These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
401 related articles for article (PubMed ID: 28053335)
41. The evaluation of biosimilarity index based on reproducibility probability for assessing follow-on biologics. Hsieh TC; Chow SC; Yang LY; Chi E Stat Med; 2013 Feb; 32(3):406-14. PubMed ID: 22899403 [TBL] [Abstract][Full Text] [Related]
42. The road from development to approval: evaluating the body of evidence to confirm biosimilarity. Declerck P; Farouk Rezk M Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv4-iv13. PubMed ID: 28903545 [TBL] [Abstract][Full Text] [Related]
43. The Legal and Regulatory Status of Biosimilars: How Product Naming and State Substitution Laws May Impact the United States Healthcare System. Paradise J Am J Law Med; 2015; 41(1):49-84. PubMed ID: 26237983 [TBL] [Abstract][Full Text] [Related]
44. Biosimilars: a regulatory perspective from America. Kay J Arthritis Res Ther; 2011 May; 13(3):112. PubMed ID: 21586106 [TBL] [Abstract][Full Text] [Related]
45. Use of Biologics and Biosimilars in Rheumatology. Sharma SK J Assoc Physicians India; 2017 May; 65(5 Suppl):9-14. PubMed ID: 28836745 [TBL] [Abstract][Full Text] [Related]
46. Midyear Commentary on Trends in Drug Delivery and Clinical Translational Medicine: Growth in Biosimilar (Complex Injectable Drug Formulation) Products Within Evolving Collaborative Regulatory Interagency (FDA, FTC, and DOJ) Practices and Enforcement. Ho RJ J Pharm Sci; 2017 Feb; 106(2):471-476. PubMed ID: 27876365 [TBL] [Abstract][Full Text] [Related]
47. Position paper from the Spanish Society of Rheumatology on biosimilar drugs. Abad Hernández MÁ; Andreu JL; Caracuel Ruiz MÁ; Belmonte Serrano MÁ; Díaz-González F; Moreno Muelas JV Reumatol Clin; 2015; 11(5):269-78. PubMed ID: 25982595 [TBL] [Abstract][Full Text] [Related]
48. Comments on the FDA draft guidance on biosimilar products. Chow SC; Endrenyi L; Lachenbruch PA Stat Med; 2013 Feb; 32(3):364-9. PubMed ID: 22903309 [TBL] [Abstract][Full Text] [Related]
49. Interchangeability Of Biological Drug Products-FDA Draft Guidance. Endrenyi L; Markus R J Biopharm Stat; 2019; 29(6):1003-1010. PubMed ID: 31023141 [TBL] [Abstract][Full Text] [Related]
50. The approval process for biosimilar erythropoiesis-stimulating agents. Wish JB Clin J Am Soc Nephrol; 2014 Sep; 9(9):1645-51. PubMed ID: 24970875 [TBL] [Abstract][Full Text] [Related]
51. State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists. Covic A; Abraham I Int Urol Nephrol; 2015 Sep; 47(9):1529-39. PubMed ID: 26223197 [TBL] [Abstract][Full Text] [Related]
57. Are biosimilars patentable? Rolfe D; Parker J; Morgan M Expert Opin Ther Pat; 2016 Aug; 26(8):871-5. PubMed ID: 27215647 [TBL] [Abstract][Full Text] [Related]
58. [Biosimilars]. Burmester GR; Müller-Ladner U Z Rheumatol; 2015 Oct; 74(8):670-1. PubMed ID: 26450433 [No Abstract] [Full Text] [Related]
59. Utilization and Treatment Costs of Tumor Necrosis Factor Inhibitors After the Introduction of Biosimilar Infliximab in the United States. Kim SC; Sarpatwari A; Landon JE; Desai RJ Arthritis Rheumatol; 2020 Jun; 72(6):1036-1038. PubMed ID: 31943866 [No Abstract] [Full Text] [Related]
60. Era of biosimilars in rheumatology: reshaping the healthcare environment. Smolen JS; Goncalves J; Quinn M; Benedetti F; Lee JY RMD Open; 2019; 5(1):e000900. PubMed ID: 31245050 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]